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Summary
The CCR5 gene encodes a cell-surface chemokine-re-
ceptor molecule that serves as a coreceptor for macro-
phage-tropic strains of HIV-1. Mutations in this gene
may alter expression or function of the protein product,
thereby altering chemokine binding/signaling or HIV-1
infection of cells that normally express CCR5 protein.
Indeed, homozygotes for a 32-bp deletion allele ofCCR5
(CCR5-D32), which causes a frameshift at amino acid
185, are relatively resistant to HIV-1 infection. Here we
report the identification of 16 additional mutations in
the coding region of the CCR5 gene, all but 3 of which
are codon altering or “nonsynonymous.” Most muta-
tions were rare (found only once or twice in the sample);
five were detected exclusively among African Americans,
whereas eight were observed only in Caucasians. The
mutations included 11 codon-altering nonsynonymous
variants, one trinucleotide deletion, one chain-termina-
tion mutant, and three synonymous mutations. The high
predominance of codon-altering alleles among CCR5
mutants (14/17 [81%], including CCR5-D32) is consis-
tent with an adaptive accumulation of function-altering
alleles for this gene, perhaps as a consequence of historic
selective pressures.
Introduction
The CCR5 gene encodes a cell-surface receptor that
binds the b-chemokines RANTES, MIP-1a, and MIP-1b
(Samson et al. 1996a), causing migration of the receptor-
bearing cell toward an increasing concentration of the
chemokine. This chemotactic response results in recruit-
ment of leukocytes to sites of inflammation (Murphy
1996; Premach and Schall 1996). A second class of li-
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gands for CCR5 were recently shown to be the envelope
glycoproteins of macrophage-tropic (M-tropic) isolates
of HIV-1 (Alkhatib et al. 1996; Choe et al. 1996; Deng
et al. 1996; Doranz et al. 1996; Dragic et al. 1996).
These isolates infect macrophages and primary T cells
and are present early after seroconversion, during the
asymptomatic period (Roos et al. 1992; Schuitemaker
et al. 1992; Connor and Ho 1994), indicating a role for
M-tropic isolates in initiation of HIV-1 infection. How-
ever, sometimes infection can occur in the absence of
CCR5 (Biti et al. 1997; O’Brien et al. 1997; Theodorou
et al. 1997), suggesting that T-tropic viruses (thosewhich
infect primary T cells and T cell lines) may also initiate
HIV-1 infection in rare cases. Identification of an allele
characterized by a 32-bp deletion in the coding region
of theCCR5 gene,CCR5-D32, has been shown to confer
near-complete protection against HIV-1 infection in in-
dividuals homozygous for the mutant allele (Dean et al.
1996; Liu et al. 1996; Samson et al. 1996b). Although
individuals homozygous for the CCR5-D32 allele fail to
express a detectable CCR5 receptor on lymphoid cell
surfaces, they display no clinical symptoms and appear
to be immunologically healthy. Since other genetically
homologous chemokine receptors bind an overlapping
set of ligands, it is possible that chemokine-receptor
functional redundancy can compensate for CCR5 ab-
sence in homozygous CCR5-D32 individuals (Premack
and Schall 1996).
On the basis of the geographic distribution of the
CCR5-D32 allele, as well as on the intrahaplotypic var-
iation determined by using flanking microsatellite loci
in strong linkage disequilibrium with CCR5-D32, we
have estimated that the 32-bp deletion occurred on the
order of 4,000 years ago (J. C. Stephens, personal com-
munication). Since that time, the allele has increased to
a frequency of as high as 13%, and perhaps higher, in
northern Europeans, but it is lacking in Africans and
Asians (Huang et al. 1996; Samson et al. 1996b; Mar-
tinson et al. 1997). The rapid increase in frequency of
this mutant allele during a relatively short period of time
suggests that selection favoring the CCR5-D32 allele
may have occurred (and, perhaps, is still occurring) in
certain populations. Had historic or ongoing selective
pressures on CCR5-D32 been operative, then other mu-
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tations in the CCR5 gene could have been objects of the
same selective pressures. Indeed, seven additional alleles
of the CCR5 gene have been identified recently in four
ethnic groups, although none of these alleles were ob-
served in the 50 Caucasians sampled (Ansari-Lari et al.
1997).
Recent studies have attempted to identify regions of
the CCR5 molecule that are important in membrane
fusion of HIV-1, and the resulting data indicate an in-
teraction, between virus and receptor, requiring multiple
sites of binding (Atchison et al. 1996; Rucker et al.
1996). However, cellular signaling through the CCR5
receptor is not required for HIV-1 fusion, and deletion
of the intracellular carboxy-terminal portion of CCR5
does not affect the ability of HIV-1 to infect cells in vitro.
Therefore, amino acid alterations in the extracellular do-
mains of CCR5 are the best candidates for inhibiting (or
enhancing) HIV-1 binding and fusion. Initial screening
of HIV-1–exposed populations for mutations in CCR5
suggests that, except for CCR5-D32, alleles of this gene
exist at a very low frequency (Dean et al. 1996). Nev-
ertheless, identification of these alleles may provide in-
formation regarding functionally significant residues/
segments of the CCR5 molecule and allow predictions
of allelic selection. Here we report the identification of
16 alleles additional toCCR5-D32, only 3 of which were
silent substitutions.
Material and Methods
DNA Samples
DNA samples were obtained from individuals partic-
ipating in one of five AIDS cohorts, which have been
described in a previous report (Dean et al. 1996).
PCR Amplification and SSCP
Variations in the nucleotide sequence of the CCR5
gene were analyzed by SSCP analysis of the following
PCR products: (1) the entire coding region of the CCR5
gene, amplified with primers F2 (5′-GGTGGAACAA-
GATGGATTAT) and R2 (5′-CATGTGCACAACTCT-
GACTG), followed by HinfI digestion, or (2) four over-
lapping segments of the gene, encompassing the entire
coding region, amplified with primer pairs F2 and R3
(5′-GCCCTGTCAAGAGTTGACAC), F2a (5′-ATGCT-
GCCGCCCAGTGGGAC) and R2a (5′-GTATGGAAA-
ATGAGAGCTGC), F3a (5′-GAAGGTCTTCATTACA-
CCTG) and R3a (5′-AGAATTCCTGGAAGGTGTTC),
and F5 (5′-TCTCTTCTGGGCTCCCTACA) and R5a
(5′-CCAGCCCACTTGAGTCCGTG). PCR amplifica-
tions and subsequent SSCP analysis were performed as
reported previously (Cullen et al. 1997).
Sequencing
Direct sequencing of PCR products was performed by
isolation of the product from an agarose gel, followed
by sequencing with Dye Terminators (Perkin-Elmer). Se-
quencing products were resolved on an ABI 373 auto-
mated sequencer, and all alleles were sequenced in both
directions.
Results
Identification and Ethnic Origins of CCR5 Mutations
Screening ∼700 Caucasians and ∼700 African Amer-
icans for variation in the coding region of the CCR5
gene resulted in the identification of 11 novel point mu-
tations, a 3-bp deletion, and four previously reported
point mutations (Ansari-Lari et al. 1997) (fig. 1 and table
1). Twelve of the 15 point mutations were nonsynony-
mous changes resulting in amino acid alterations, and
three were synonymous. Eleven point mutations repre-
sent transversions, and four represent transitions. All
alleles of CCR5 that are shown in table 1 are found at
low frequencies relative to the wild-type and CCR5-D32
alleles. Eight of the mutations were identified only in
Caucasians, five were found exclusively among African
Americans, one was found only in a Hispanic, and two
mutations, L55Q and A335V, were present in both Cau-
casians and African Americans. The higher frequency of
the L55Q mutation in Caucasians (.041) compared with
that in African Americans (.006) suggests that the allele
was added to the pool of CCR5 polymorphisms in Af-
rican Americans because of recent admixture. Alterna-
tively, the A335V mutation is found at a higher fre-
quency in African Americans than in Caucasians and
therefore may either be older than the split between the
two groups or be of recent African originwith admixture
to Caucasians.
Location and Conservation of Mutations
An alignment of the human CCR5 amino acid se-
quence with other chemokine-receptor sequences is
shown in figure 1A. Seven of the mutations (C20S,
L55Q, A73V, C101X, R223Q, 228DK, and G301V)
have occurred at positions that are highly conserved
throughout b-chemokine receptors; of these seven, three
(C20S, C101X, and G301V) are conserved in the a-
chemokine receptor, CXCR4, as well.
Mutations in the CCR5 gene resulted in amino acid
alterations throughout the molecule, with a slight con-
centration near the N-terminus (fig. 1B). Furthermore,
mutations were observed in regions of the gene encoding
transmembrane, intracellular, and extracellular domains
of the molecule. Since the conserved cysteine at position
20 is proposed to form a disulfide bond with cysteine
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Figure 1 Amino acid sequence variation in the CCR5 protein. A, Sequence alignment of five b-chemokine receptors and the a-chemokine
receptor, CXCR4. Positions in the CCR5 protein having altered amino acids, as deduced from the nucleotide sequence, are shown above the
wild-type CCR5 sequence. A dot (.) denotes the absence of an amino acid, and underlining denotes segments that are proposed transmembrane
regions of the molecule. B, Diagram of the CCR5 molecule spanning the membrane. Positions where alterations were identified have been
blackened. The arrow indicates the beginning of the region affected by the D32 mutation.
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Table 1
Genetic Variants of the CCR5 Gene
VARIANTa
NUCLEIC
ACID
SUBSTITUTION
NO. OF ALELLES OBSERVED/TOTAL NO. OF CHROMOSOMES (FREQUENCY)b
Caucasians African Americans
I12L A25C 1/382 (.003) 0/664 (.0)
C20S T58A 2/698 (.003) 0/664 (.0)
A29S G85T NT 1/64 (.015)
I42F A124T 1/170 (.001) NT
L55Q T164A 29/708 (.041) 5/664 (.007)
R60S G180T NT 1/76 (.013)
A73V C218T 3/462 (.002) 0/664 (.0)
S75S T215Cc 0/212 (.0) 9/664 (.013)
C101X T303A NT 1/70 (.014)
I164I C492Ac 1/98 (.010) NT
D32(185) D32 520/5,210 (.10) 38/2,030 (.019)
R223Q G668A 1/64 (.016) NT
228delK 680del3 1/490 (.002) 0/494 (.0)
V300Vc,d C900A 1/242 (.0) 0/100 (.0)
G301V G902T 1/90 (.011) 0/268 (.0)
A335V C1004T 1/174 (.006) 12/484 (.025)
Y339F A1016T 0/242 (.0) 3/116 (.026)
a Except in the case of 228delK, the first letter in each entry denotes the wild-type amino acid; the number denotes
the position; and the letter following the number denotes the mutated amino acid; 228delK is a triplet deletion of
lysine (K) at position 228. In the case of I12L, A29S, and Y339F, the substitutions are conservative, based on net
charge; all other substitutions are nonconservative, resulting in alteration of amino acid charge.
b “NT” denotes that controls for the variants were not included on gels representing that particular region; thus,
it is not certain that the variant would have been identifiable if it indeed had been present on that gel.
c Synonymous, non–codon altering.
d Found in a single Hispanic individual.
at position 269 (Combadiere et al. 1996; Samson et al.
1996a), the C20S mutation located extracellularly near
the N-terminus is very likely to alter ligand binding to
CCR5.
Clinical Data in Individuals Having Novel CCR5
Alleles
Cohorts of individuals at high risk for HIV-1 infection
were chosen for screening the CCR5 gene for mutations,
in order to identify potential alleles (in addition to
CCR5-D32) affecting virus infectivity or progression to
AIDS. Unlike CCR5-D32, none of the novel alleles were
found at a frequency high enough to allow evaluation
of a potential role in protection against HIV-1, when a
population-survey approach was used. Indeed, no in-
dividuals were discovered who were homozygous for
any of the novel alleles. There were, however, several
individuals heterozygous for a rare mutation and the
CCR5-D32 allele. Since CCR5-D32 has been shown to
confer strong resistance to HIV-1 infection among ho-
mozygotes, as well as postponement of AIDS progres-
sion among CCR5-/D32 heterozygotes (Dean et al.
1996; Huang et al. 1996; Michael et al. 1997; Smith et
al. 1997; Zimmerman et al. 1997), we examined the
clinical outcomes of individuals with novel mutations,
to detect evidence for protection against HIV-1 infection
or progression to AIDS or both (table 2).
Four nonsynonymous variants (I12L, I42F, L55Q, and
A73V) were found as heterozygotes with CCR5-D32,
and patients heterozygous for all but I42F includedHIV-
1–infected patients. The position-42 isoleucine, which is
altered in the I42F, is conserved between CCR5 and
CCR2 (fig. 1A), as well as among CCR5 in other species.
Patients with mutations I12L or A73V heterozygous
with CCR5-D32 were infected with HIV-1, although the
I12L/CCR5-D32 heterozygotes have survived nearly 14
years without progressing to AIDS, an observation con-
sistent with possible protection in AIDS progression.
The more common L55Q and A335V mutations oc-
curred in both Caucasian and African American indi-
viduals. Of six L55Q/CCR5-D32 heterozygotes, four
were infected with HIV-1 and twowere not. The infected
individuals progressed to AIDS in 8.2–14.1 years (table
2), which is not different from the median time to AIDS,
10–12 years, indicating no obvious effect of this mu-
tation on infection or disease progression. There were
no A335V/CCR5-D32 heterozygotes observed, preclud-
ing an analysis of infection restriction by this CCR5-
variant molecule. The genotypeCCR5-/A335V did not
display an obvious effect on progression to AIDS, since
three patients progressed to AIDS in 5–7 years, but oth-
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Table 2
Clinical Description of Individuals with CCR5 Alleles Altering Amino Acid Sequences
Variant
(Patient) Risk Group Race HIV-1 Status AIDS Statusa
No. of Years
HIV1 Positive and
AIDS Negativeb CCR5-D32 Genotypec
I12L Hemophilia Caucasian Positive Negative 13.6 /CCR5-D32
C20S(1) Homosexual Caucasian Positive Negative 15.1 /
C20S(2) Homosexual Caucasian Positive Positive 12.2 /
A29S IV drug user African American Positive Negative 5.7 /
I42F Homosexual Caucasian Negative Negative NA /CCR5-D32
L55Q(1)d Hemophilia African American Positive Negative 8 /
L55Q(2) IV drug user African American Positive Negative 7.4 /
L55Q(3) IV drug user African American Positive Negative 8.5 /
L55Q(4) IV drug user African American Negative Negative NA /
L55Q(5) IV drug user African American Negative Negative NA /
R60S IV drug user African American Negative Negative NA /
A73V(1) Hemophilia Caucasian Positive Positive 11.9 /CCR5-D32
A73V(2) IV drug user Caucasian Negative Negative NA /
A73V(3) Homosexual Caucasian Positive Positive 7.8 /CCR5-D32
C101X IV drug user African American Positive Negative 6.3 /
R223Q Homosexual Caucasian Positive Positive 13.1 /
228delK IV drug user Caucasian Positive Negative 11.3 /
G301V Homosexual Caucasian Positive Negative 15.2 /
A335Ve Hemophilia Caucasian Positive Negative 14.9 /
Y339F(1) Hemophilia African American Positive Positive 10.5 /
Y339F(2) IV drug user African American Positive Negative 7.3 /
Y339F(3) IV drug user African American Positive Negative 2.8 /
a According to 1987 CDC definition.
b NA  not applicable.
c A plus sign () denotes the wild-type allele.
d In the text, 34 Caucasians with L55Q are discussed.
e In the text, 12 African Americans with A335V are discussed.
ers have remained AIDS free for 7–9 years. One HIV-
1–infected individual of this genotype has remained
healthy for 14.9 years. Several mutations (C2OS,
R223Q, 228delK, I12L, and G301V) were found exclu-
sively in individuals who were HIV positive and AIDS
negative for 111 years. In vitro analysis to determine the
effect of these alterations on HIV-1 infection is in
progress.
Discussion
A large number of individuals homozygous forCCR5-
D32 have now been identified, and the single naturally
occurring phenotype observed in individuals with this
genotype is resistance to HIV-1 infection. Since homo-
zygosity for the CCR5-D32 allele results in absence of
CCR5 on the cell surface, absence of the CCR5 protein
does not have any obvious health consequences. This
notion is quite reasonable, given the large number of
chemokine receptors that have similar functions and
overlapping ligands (Premack and Schall 1996). The
CCR5-D32 allele appears to have originated within the
past 4,000 years and may have arisen to its present fre-
quency of 10%–15% in Caucasians because of selection
against some function of the receptor (J. C. Stephens,
personal communication). If the selective force that
drove CCR5-D32 to its present frequency in Caucasians
persisted for a long period, then one also might expect
additional mutations that alter the function of theCCR5
gene to accumulate in the population.
A recent report by Ansari-Lari et al. (1997) has de-
scribed seven CCR5 variants, in addition to CCR5-D32,
that have been observed in African Americans, Hispan-
ics, Chinese, and/or Japanese but not in the 50 American
Caucasians tested. Four of these variants—L55Q,
R223Q, A335V, and Y339F—were also observed in our
sample, and two of them (L55Q and R223Q) appear to
be of Caucasian origin. Given the frequency of L55Q in
our Caucasian population (.04), it is surprising that this
allele was not observed in the 50 Caucasians sampled
by Ansari-Lari et al. A possible explanation for the dif-
ference between the number of variants that Ansari-Lari
et al. observed in Caucasians and that observed in our
study could be the fact that our sample included only
individuals from cohorts at high risk for HIV-1 infection,
rather than a random sampling. If so, then it is likely
that the variants may have an effect on HIV-1 infectivity
or progression to AIDS. However, this explanation is
not supported by the observation that the number of
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variants found in the African American samples was
similar in the two reports.
Conservation of an amino acid within a family of
proteins can indicate the importance of that amino acid
to a common function in that protein family; therefore,
it is useful to consider the sites of amino acid variation
that are deduced from the novel CCR5 alleles. Several
of the 13 nonsynonymous mutations reported herein oc-
curred at positions that are conserved throughout mem-
bers of the b-chemokine–receptor family, and three of
these (C20, C101, and G301) are conserved in the a-
chemokine receptor, CXCR4, as well. All of the missense
mutations that occurred at conserved positions were of
Caucasian origin, whereas those in African American
individuals appear at amino acid sites that vary among
chemokine receptors and that may more readily tolerate
amino acid substitutions.
Given the striking difference between CCR5-D32 al-
lele frequency in Africa and that in Europe, it is not
unlikely that historic selective events (e.g., infectious-
disease outbreaks mediated by pathogens that utilize
CCR5 as does HIV-1) may also have influenced the per-
sistence of CCR5 missense mutations that occur today
among Africans. We cannot exclude, however, the pos-
sibility that the difference between the mutation fre-
quencies in Africans and those in Caucasians reflects a
bias in our sample of patients at risk for HIV-1.
Additional evidence suggesting a history of selective
pressure targeting CCR5 mutations is derived from the
relatively high proportion of nonsynonymous, or codon-
altering, mutations. Of 19 genetic variants described (ta-
ble 1; also see Ansari-Lari et al. 1997) 15 (79%) were
nonsynonymous. Li (1997) reported, in a comparison of
49 human genes to mouse homologues, that an average
of 16% of all substitutions were nonsynonymous. An
analysis of the CCR5 gene shows that 40% of the hu-
man:mouse nucleotide substitutions are nonsynony-
mous. For the human:macaque CCR5 sequence com-
parison, 33% of the substitutions are nonsynonymous.
The high incidence (79%) of nonsynonymous substi-
tutions among human variants is a highly significant
elevation ( , ) of the incidence of co-2x  13.5 P ! .0003
don-altering mutations. These results can be interpreted
in at least two scenarios: it could be that (1) most CCR5
amino acid substitutions do not affect normal CCR5
function or (2) amino acid substitutions do affect CCR5
function negatively but confer some other adaptive ben-
efit. The latter explanation is consistent with the CCR5
role in HIV pathogenesis (Dean et al. 1996; Huang et
al. 1996; Michael et al. 1997).
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